Search
BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions
CEO Paul Hastings describes his opinion of the benefits of an NK cell approach over T-cells, and discusses the work Nkarta has done to get to a high dose that should tell a clear story of the profile of this by year end. Coverage brought to you by
3 hours ago
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....
Jun 17, 2025
Nkarta CEO Paul Hastings on NK based cell therapies for autoimmune conditions
Paul Hastings describes why Nkarta believes NK based therapies are uniquely fit for this area.
Mar 27, 2024
BIO Chairman and Nkarta CEO talks biotech
Current BIO Chairman and Nkarta CEO Paul Hastings talks about the policy changes that have been affecting biotech lately, and NK cells.
Apr 28, 2023
.png){kind=logo}